Corticotropin-releasing factor-binding protein (CRF-BP) is known to regulate the bioavailability of CRF and may also play a role in stress behaviours. CRF-BP has been localized in the pituitary as well as central nervous system (CNS) limbic and cortical areas, including the amygdala. The signal transduction pathways which regulate amygdalar CRF-BP are not well understood. In this report, we have examined the effect of protein kinase A and C activators, CRF, dexamethasone and interleukin-6 (IL6) on CRF-BP mRNA and protein expression in dissociated fetal amygdalar cultures.
totally removed at day 5 and replaced by fresh medium containing cytosine secretion by binding to CRF and inhibiting its ACTH releasarabinoside (AraC; 20 mM ) to limit the proliferation of glial cells (14) .
ing activity (9) . This has been demonstrated in rat primary pituitary cultures (8) as well as in cultured mouse anterior Immunocytochemistry pituitary cells (7) .
The ABC method using a VectaStain kit ( Vector Labs, Burlingame, CA, USA) was utilized using a rabbit antibody to CRF-BP (provided by W. Vale, It has been hypothesized that CRF-BP levels may modulate PhD, Salk Institute, La Jolla, CA, USA). Protocols from Vector Labs were the HPA axis in response to stress. Following restraint stress, utilised. Tissue was incubated initially with normal goat serum with 2% steady state levels of pituitary CRF-BP mRNA increase 2-3 bovine serum albumin (BSA) for 30 min at room temperature to block nontimes over basal levels of expression for up to 2 h after the specific binding and then incubated with the CRF-BP antibody (152000) restraint (10) . CRF-BP has also been detected in numerous overnight at 4°C. This was followed by a 30-min incubation at 4°C with biotinylated IgG ( Vector Laboratories, Burlingame, CA, USA) and then with limbic regions, including the amygdala (9) signal transduction pathways responsible for amygdalar (15 The membrane was incubated with rabbit antihuman CRF-BP (1510 000): overnight 0.05 U/ml of penicillin-streptomycin (Sigma, Gaithersburg, MD, USA). Cells were collected by centrifugation (500×g, 5 min), resuspended in SFM suppleat 4¡C. After washing, the membrane was incubated with goat antirabbit antibody (151000; Vector). The membrane was washed at room temperature mented with 7.5% foetal calf serum (Atlanta Biologicals, Norcross, GA, USA). For analysis of CRF-BP peptide and mRNA, cells were plated at a and the immunoreactive protein bands were detected using the enhanced chemiluminescence ECL kit (Amersham). The membrane was exposed to density of 3.5 million cells/100 mm tissue culture dishes (Falcon, Franklin Lakes, NJ, USA). For microscopic analysis, cells were grown in 8-well LabXomatic film ( Kodak) for 2-60 s and then developed. A Foto/Eclipse Imager ( Fotodyne, Inc.), interfaced with a Power Macintosh 8100/110 using NIH Tek II Chamber Slide Systems at 75 000 cells per well (Nalge Nunc International, Naperville, IL, USA).
ImageQuant analysis software, was used for densitometric analysis of band intensity. This was normalized to total protein per lane of loaded lysate. We coated the plates with gelatin (250 mg/ml, 30 min, room temperature; Sigma) and polyornithine (MW=40 000; 1.5 mg/ml, overnight at room Rainbow markers (Gibco BRL) were used to estimate protein size. Recombinant CRF-BP(25 pg) served as a positive control (provided by temperature; Sigma) based on Brouard et al. (11) . Following plating, cells were incubated at 37°C in a 95% O 2 /5% CO 2 atmosphere. Medium was Dr Vale).
Transfection
Cells were transfected in six well plates (Falcon, Lincoln Park, NJ, USA) with a CRF-BP-chloramphenicol acetyltransferase (CAT ) plasmid and treated with the same stimuli utilised above. Cells were transfected at a density of 2×106 using the Lipofectamine Reagent (Gibco-BRL). The 3,500 CRF-BP-CAT plasmid utilized contained a 3500 base pair SacI fragment of the rat CRF-BP gene, #3500 base pairs of 5∞ flanking DNA and 66 base pairs of 5∞ untranslated sequences from exon 1. This was linked to the promoterless reporter plasmid, pGSVOCAT (18) . Four mg of 3500 CRF-BP-CAT and 1 mg of pSV-b-galactosidase control vector (Promega) were diluted in OptiMem medium with the Lipofectamine reagent (Gibco-BRL) based on the manufacturer's recommended procedures. DNA solution was then added to the cells and incubated at 37°C for 2-3 h. Following a 36-h incubation at 37°C in serum containing medium, cells were then treated 15 h with either 100 nM CRF, 30 mM forskolin, 100 pM IL6 or 50 nM TPA or 8 h with 100 nM dexamethasone in serum free b-pit Julip medium containing 0.1% BSA. After treatment, cells were lysed using 100 ml of 250 mM Tris pH 8, 0.5% Triton X-100 and rapidly frozen on dry ice. CAT assay was performed with 80 ml of cell extract using the Quan-T-CAT assay system (Amersham). The pSVb-galactosidase was included to control for differences in transfection efficiency and b-galactosidase was assayed based on the Promega protocol. Levels of CAT expression were normalized to b-galactosidase. In addition, as a control we transfected cells with the promoterless reporter plasmid, pGSVOCAT.
Statistical analysis
The quantitative data obtained were expressed as mean+SEM. Data were subjected to ANOVA followed by Duncan's Multiple Range Test using INSTAT Software (Loyola University Medical Center, Chicago, IL, USA). A P-value <0.05 was considered sufficient to reject the null hypothesis. Figure 1 illustrates a typical amygdalar culture stained with anti-CRF-BP antibody 17 days following dispersion. The size of the CRF-BP transcript in these cells was 1.85 kilobases as observable in other systems (data not shown; (8, the quantitative changes in levels of CRF-BP mRNA with increasing concentrations of CRF when corrected to 28S. 19)). Figure 2 depicts changes in CRF-BP mRNA following 12 h of treatment with various concentrations of CRF. We
Results

Morphology of amygdalar CRF-BP cells in vitro
Concentrations of CRF at 100 and 1000 nM lead to significant increases in CRF-BP mRNA expression (P<0.05). initially examined time course changes with 1000 nM CRF treatment at 6, 9, 12, 18 and 24 h (data not shown). The Changes in CRF-BP mRNA following 12 h treatment with various concentrations of TPA, IL6, dexamethasone or forpeak CRF-BP mRNA expression following CRF treatment occurred at 12 h. The same was true when other treatments skolin are depicted in Fig. 3 . A representative autoradiogram is shown at the top of each figure and depicts the CRF-BP were administered so that this time was chosen to examine concentration-dependent effects of CRF and the other commRNA and 28S changes observable in autoradiograms with concentrations of the various agents. The lower portion of pounds. The autoradiograms in the upper portion of Fig. 2 depicts the CRF-BP mRNA and 28S ribosomal RNA(28S) each of the figures reveals the quantitative changes in levels of CRF-BP mRNA corrected to 28S with increasing concenchanges with CRF concentrations of 0, 1, 10, 100 and 1000 nM. The 28S blots showed no change in signal as a trations of each agent. Concentrations of the following agents lead to significant increases in CRF-BP mRNA expression result of CRF or any subsequent challenge and were used to correct the CRF-BP Northern blot for differences in RNA (P<0.05): 100 pM IL6, 500 pM IL6, 100 nM DEX, 50 nM TPA and 30 mM forskolin. loading. The histogram in the lower portion of Fig. 2 
reveals
Response of the rat CRF-BP promoter in primary amygdalar cultures to stimuli
Primary cultures were transfected with a CRF-BP reporter construct to determine whether similar patterns of regulation would be observed between transfection assays and endogenous CRF-BP gene expression. The times of incubation were chosen based on preliminary experiments (data not shown) which revealed when maximal increases in expression occurred. The results from the transfection studies are depicted in Fig. 5 . Transfections with the rat CRF-BP promoter-CAT construct followed by treatment with all 5 agents produced qualitatively similar results as observed above (P<0.05, n=3 for all ) suggesting that the DNA sequences required for regulation by CRF, cAMP, TPA, IL6 and dexamethasone are contained within the 3500 base pair of CRF-BP DNA. Transfection of the cultures with a pGSVOCAT construct lacking the 3500 base pair of 5∞ flanking DNA yielded levels of CAT expression which were no different from that observed in cells which were not transfected.
Discussion
Primary amygdalar cultures have been utilised in the past to analyse the actions of stimuli on CRF expression (13) . We have now used this experimental model to study the regulation of CRF-BP expression. We first determined that our amygdalar cultures express CRF-BP which is detectable by immunocytochemistry, Western blot and Northern blot analysis. In addition, we have demonstrated that the expression of CRF-BP is regulated insofar as various agents such as CRF, CRF-BP levels achieved with forskolin vs dexamethasone. Our Western blots detected higher levels of protein expression with dexamethasone relative to forskolin; with Northern blots, the opposite was true. The reason for this is unknown Regulation of CRF-BP expression in primary amygdalar although relative differences in message or protein stability cultures may be a contributing factor. We questioned whether the expression of CRF-BP was
The behavioural and physiologic relevance of the small responsive to the same agents which increased CRF-BP changes in mRNA and protein expression we observed remain mRNA expression. We performed semiquantitative Western to be determined. It is possible that levels of CRF-BP mRNA analysis of total cellular protein after 24 h treatment with induction achieved with these agents could have been greater 30 mM forskolin, 100 nM dexamethasone, 100 pM IL6, if higher concentrations of stimuli were used in the culture 50 nM TPA or 100 nM CRF. The results are depicted in system. The increases in CRF-BP expression observable in Fig. 4 . The upper portion of Fig. 4 depicts a representative our system were, however, comparable to that reported by Western blot with the various treatments. The histogram in others following the administration of similar stimuli. For  Fig. 4 reveals the semiquantitative densitometric analysis instance, intraventricular injections of IL6 in rats will signiobtained with each treatment. Significant increases were ficantly increase metallothionen-II protein levels to approximately 120% of baseline (20) . In addition, intravenous observable with all treatments (P<0.05; n=3 for all ). The net result of such a dual effect would be expected to alter the bioavailability of CRF.
There is evidence from various model systems that agents injections of IL6 in rats result in significant 20% increases in hippocampal 5-HIAA levels relative to control (21) .
such as protein kinase activators can modulate CRF-BP expression. In mixed neuronal and pure astrocyte cultures, Cross talk between various signal transduction pathways may occur in the amygdala in vivo and this mechanism may activators of protein kinase A (PKA) and PKC will increase CRF-BP expression (17) . Transfection experiments with be one way in which the small changes in CRF-BP expression we observed may be amplified with multiple stimuli. For CRF-BP reporter constructs in tumour derived cell lines demonstrate positive regulation of the CRF-BP promoter by instance, the STAT5 and glucocorticoid receptor pathways are known to interact synergistically to enhance casein gene protein kinase A and by CRF in cells expressing the CRFreceptor (18) . In an immortalized amygdalar cell line, CRF, expression (22) . Furthermore, STAT5 is known to play a role in activating the c-fos gene and in this manner, IL-6 and forskolin, IL6, TPA and dexamethasone will also stimulate CRF-BP expression. The results from our observations in protein kinase C (PKC ) pathways may also converge (23) . It is also of interest that some agents which increase the dissociated amygdalar cultures are entirely consistent with all of these findings and furthermore appear to validate the expression of CRF in amygdalar cultures also increase the expression of CRF-BP. We had previously demonstrated that immortalized amygdalar cell line as a useful model of CRF-BP expression (19) . forskolin and IL6 will increase CRF expression in dissociated In contrast, the responses of CRF and CRF-BP to dexa-(28). To what extent our cell dispersion procedure promotes a biological situation similar to inflammation or injury is methasone are distinct in the dissociated amygdalar cultures. Previously we reported a lack of response of CRF mRNA in unclear.
It is not clear which response elements in the CRF-BP dissociated amygdalar cultures to dexamethasone (13 (26) demonstrated that adrenalectomy does not alter the expreswhich five out of the six consensus base pairs can be found. Likewise, for the other STAT binding elements, there are two sion of CRF in the amygdala. Although dexamethasone did not alter CRF levels in our previous studies with primary regions which contain five out of the required six base pairs. One of these is located from −201 to −193 and another is amygdalar cultures, we found here that dexamethasone will alter levels of the CRF-BP intracellularly. This provides a located from −481 to −473. It is possible that these regions interact with STAT proteins to alter CRF-BP gene expression. potential mechanism by which steroids can regulate CRF indirectly through actions on its binding protein.
Alternatively, consensus STAT binding elements which transduce the actions of IL6 could also be present further The positive regulatory effect of dexamethasone on CRF-BP in the pituitary is consistent with what we have upstream.
Increased understanding of the mechanisms regulating observed in primary amygdalar cultures. In vivo, glucocorticoids positively regulate CRF-BP expression in the pituitary CRF-BP expression in the amygdala is important because of the implied link between CRF expression and CRF-BP as (10) . This is based on the finding that adrenalectomy will decrease rat pituitary CRF-BP expression. Other signal transcoregulators and their potential role in the behavioural manifestations of stress. The studies in this report demonduction pathways regulating CRF-BP expression in the pituitary have not yet been investigated.
strate that amygdalar CRF-BP appears to be positively regulated by a variety of stimuli-the cytokine IL6, activators The rat CRF-BP gene is known to contain CRE and AP-1 sites (18) . AP-1 sites have been located at basepairs -177 to of the PKA and PKC intracellular pathway, dexamethasone and, more importantly CRF. The elucidation of these signal -171, −196 to −190 and from −238 to −232. It is likely that one or more of these sites mediate the TPA effect transduction mechanisms are likely to be important in understanding the molecular basis of stress related behavioural observable in our studies. Likewise the CRE at −127 to −123 likely accounts for the forskolin effect in our experialterations in the amygdala such as those involving anxiety or fear and even possibly depressive and anxiety disorders. ments. No consensus glucocorticoid response element (GRE ) sequence is present in the 700 base pairs 5∞ to the CRF-BP transcript start site. However, a GRE could be present further
